13 results about "PCA3" patented technology

The invention discloses a digital micro-droplet RNA amplification detection system for prostatic cancer and application of PCA3 combined with an ERG gene in the system, and belongs to the technical field of tumor diagnosis. The digital micro-droplet RNA amplification detection system for prostatic cancer comprises reagents for respectively and specifically detecting the following genes based on a real-time fluorescent nucleic acid isothermal amplification method: PCA3, ERG and SPDEF, and a digital PCR system. Compared with the existing kit or other products for detecting the prostate cancer, the digital micro-droplet RNA amplification detection system provided by the invention has the advantages that the detection omission ratio of the prostate cancer is greatly reduced, and the detection sensitivity and the negative predictive value of the prostate cancer are improved.

The invention relates to a kit for detecting prostate, the kit for detecting prostate comprises an RT-RAA amplification system, the RT-RAA amplification system comprises an RT-RAA amplification stock solution and an RNA sample, the RT-RAA amplification system comprises T7RNA polymerase with the concentration of 2-6 U / [mu] L, and the T7RNA polymerase is used for being mixed with the RNA sample from a sample to be detected to prepare an RNA product; the primer pair and the probe are used for preparing an RNA product; the fluorescent test strip comprises three positions, namely a PCA3 detection line, a PSA detection line and a negative sample quality control line, the PSA detection line is coated with an anti-PSA rabbit-derived antibody and is used for being combined with PSA protein in a sample to be detected, the PCA3 detection line is coated with an anti-FITC rabbit-derived antibody marked by fluorescent microspheres and is used for being combined with target RNA in an RNA product, and the PCA3 detection line is used for being combined with the target RNA in the sample to be detected. And the negative sample quality control line is coated with a ligand Avidin of Biotin, can be combined with an antibody in the combination pad, and is used for judging whether the chromatography process is smooth or not. The kit for detecting the prostate has good sensitivity and accuracy.

The invention discloses a preparation method and application of a long-chain non-coding RNA response type nano motor probe for urine PCA3 detection, and belongs to the field of nano medicine. The technical problem to be solved by the invention is to provide a nucleic acid response type Janus nano motor probe for accurately and rapidly detecting PCA3 in urine. According to the method, a PCA3 sequence is used as a target lncRNA, and stem-loop hDNA molecules marked with NIR fluorescence and quenching molecules are innovatively and directionally assembled with Fe3O4 / Au nanoparticles and Urease, so that the Janus nano motor probe (Janus hDNA-Fe3O4 / Au-Urease) with a magnetic enrichment effect is formed. Urease catalyzes urea to generate gas, so that the Janus nano-motor probe prepared by the invention can autonomously move in a complex biological environment (urine and tumor cells), thereby realizing efficient recognition of PCA3. On the basis of a pairing effect with a characteristic sequence in a PCA3 long chain, the stem-loop hDNA molecule and the quenching molecule are disassembled, so that an NIR fluorescence signal of the nanoprobe is lightened.

Disclosed in the present invention are a digital droplet RNA amplification detection system for prostate cancer and a method for reducing the false negative rate of prostate cancer. The provided digital droplet RNA amplification detection system for prostate cancer comprises reagents for respectively and specifically detecting the following genes on the basis of a real-time fluorescent nucleic acid constant-temperature amplification method: PCA3, ERG and SPDEF, and a digital PCR system.

This invention belongs to the field of biodetection technology and discloses a fluorescence detection method for the prostate cancer biomarker PCA3 based on gold nanorods and CRISPR Cas12a amplification. This invention provides a detection kit for the ultrasensitive detection of the long non-coding RNA PCA3, a tumor marker for prostate cancer. This kit utilizes the paracleavage property of CRISPR Cas12a activated by the target sequence to cleave the fluorescent reporter probe, releasing the fluorophore. This removes the signal quenching effect of the gold nanorods on the fluorophore, restoring the fluorescence signal and achieving ultrasensitive detection of the target sequence. The limit of detection (LOD) of this kit is as low as 1.65 pM, achieving highly selective quantitative detection of PCA3.

Provided herein are human EIF3L binding molecules and nucleic acid sequences encoding such molecules. In particular embodiments, provided herein are human EIF3L binding molecules (e.g., monoclonal antibodies or antigen binding fragments thereof) having particular light and / or heavy chains variable regions, or light chain and / or heavy chain CDRs, and methods for using such molecules, and / or other EIF3L binding molecules, and / or CD63 binding molecules, to treat a prothrombotic condition that is accompanied by pathological exosome production in subjects (e.g., human subjects with tumor-mediated thrombosis). In some embodiments, the presence or level of cancer is detected by detecting CD63 positive, and / or PCA3 positive, and / or EIF3L-positive, exosomes in a sample.

The invention provides a prostate cancer detection kit, a detection system, a detection method and application, the kit simultaneously detects Ct values of PCA3 and PSA in a urine sample, namely CtPCA3 and CtPSA; the kit comprises a first specific amplification primer and a probe group aiming at a PCA3 gene, and a second specific amplification primer and a probe group aiming at a PSA gene, the kit interprets the detection result according to the delta Ct value, and delta Ct = CtPCA3-CtPSA. The detection kit and the detection system have the advantages of simple operation process, short time consumption, simple result interpretation method, good result repeatability and specificity, and high coincidence rate with clinical evaluation indexes.

The invention provides a prostate cancer detection method and kit based on exosome RNA, and the method comprises the following steps: preparing nano-scale cationic lipid particles coated with RNA molecular beacons, each RNA molecular beacon is combined with a corresponding target exosome to generate fluorescence, and the fluorescence is used for detecting the prostate cancer. The target exosome is allowed to be one or more of the following exosomes in the urine: miR-141, miR-375, PCA3 and T1-E2; a porous chip plate is coated with an exosome capture system and nanoscale cationic lipid particles to form the detection kit; the exosome capturing system is used for capturing exosomes; a to-be-detected sample is pretreated, the pretreated to-be-detected sample is added into the kit, and whether a subject suffers from the prostate cancer or not is judged according to a fluorescence imaging result of the kit; wherein the to-be-detected sample at least comprises urine of a subject, non-invasive detection of prostatic cancer can be realized, the detection cost is low, the time is short, and the cost is relatively low.

The invention discloses an unmarked universal immunosensor as well as preparation and application thereof, zirconium source ZrCl4 and H2BDC organic ligand are taken as precursors, the precursors are compounded with two-dimensional MXene by adopting a one-step solvothermal method, and an MOF / MXene composite material is successfully prepared. The MOF / MXene composite material has excellent electrochemical oxidation-reduction catalytic performance, and is coupled with different target antibodies / aptamers through carboxyl functional modification to construct an electrochemical sensor; by optimizing antibody / aptamer coupling and detection parameters, the optimized immunosensor respectively realizes unmarked high-sensitivity detection of PCA3 (the detection range is 0.01-100pM) and AFP (the detection range is 0.01-50ng / mL), and a universal platform can be provided for trace detection of different tumor markers.

The invention relates to the technical field of disease diagnosis, and provides a probe, a detection reagent and a kit for detecting PCA3 in urine and a use method thereof. The probe is as shown in SEQ ID NO. 4; a position which is 34nt away from a 5'end of a nucleotide sequence of the probe and is more than or equal to 15nt away from a 3 'end is marked with tetrahydrofuran, a T basic group at the upstream of a tetrahydrofuran site is marked with a fluorophore, a T basic group at the downstream of the tetrahydrofuran site is marked with a quench group, the distance between the fluorophore and the quench group is 2-4nt, and the distance between the fluorophore and the quench group is 2-4nt. According to the present invention, the multi-enzyme isothermal rapid amplification and the CRISPR / Cas12a system are combined, such that the amplification of the fluorescence detection signal is achieved, the one-tube reaction of the in vitro amplification and the CRISPR / Cas12a shearing is achieved, and the aerosol pollution is avoided;

The utility model discloses a prostate cancer PCA3 detection sample storing and taking device which comprises a cylinder, a piston is slidably connected to the interior of the cylinder, a pull rod is connected to the piston, a pressing plate is connected to the end, extending out of the cylinder, of the pull rod, an adjusting ring is connected to the outer side wall of the cylinder, an adjusting rod is arranged in the adjusting ring in a penetrating mode, and the pressing plate is connected to the outer side wall of the cylinder. The adjusting ring is provided with a positioning piece used for limiting sliding of the adjusting rod, one end of the adjusting rod is connected with a limiting block, and the outer side wall of the drawing rod is connected with a positioning block used for abutting against the limiting block. According to the volume of a sample needing to be sucked, the position of the adjusting rod is adjusted, a worker pulls the drawing rod through the pressing plate to suck the sample, and when the sample in the barrel reaches the specific volume, the positioning block on the drawing rod abuts against the limiting block to limit the piston to continue to move, so that the sample of the specific volume is quickly sucked, the structure is accurate, and operation is convenient. Efficiency is high, and time and labor are saved.

The invention discloses an application of an exosome PCA3, AMACR and MALAT gene combination in early diagnosis of prostatic cancer. The exosome is obtained through an ultrafiltration method, and the purpose of early diagnosis of prostatic cancer is achieved by detecting the transcriptional level of genes PCA3, AMACR and MALAT1 in the exosome. The detection sensitivity can reach 91.2%, the specificity is 84.7%, the positive predictive value is 83.7%, the negative predictive value is 91.7, and excessive diagnosis and treatment are reduced. The painless puncture-free diagnosis mode relieves the pain of the patient and saves the cost of unnecessary puncture.

Provided are a digital microdroplet RNA amplification detection system and method for reducing the missed detection rate of prostate cancer, which belong to the technical field of tumor diagnosis. The provided digital microdroplet RNA amplification detection system for reducing the missed detection rate of prostate cancer comprises: reagents based on a real-time fluorescent nucleic acid isothermal amplification method for specifically detecting the following genes, respectively: PCA3, ERG, and SPDEF; and a digital PCR system. Compared with existing kits or other products for prostate cancer detection, the provided digital microdroplet RNA amplification detection system can significantly reduce the missed detection rate of prostate cancer and improve the detection sensitivity and negative predictive value for prostate cancer.